Dr. Xuedong Dai, Ph.D. in Organic Chemistry and Postdoctoral at MIT, as the executive VP of International Discovery Service Unit in Medicilon, he has been deeply involved in the research and development of chemical drugs for central nervous system diseases, infectious diseases and tumor diseases for more than 20 years. Dr. Dai has a deep understanding and rich experience in the process of drug discovery, including the identification and optimization of seed compounds, and the development of high-quality clinical candidate compounds. Dr. Dai participated in the research and development of drugs including marketed drugs, such as Horizant®/Regnite®; clinical drugs, such as JNJ-75276617; and clinical candidate compounds, such as Arbaclofen Placarbil, XP21279, XP23829, etc.
Shanghai Medicilon Inc.
Address: No. 585, Chuanda Road, Pudong, Shanghai, 201200, China